journal
MENU ▼
Read by QxMD icon Read
search

Journal of the National Comprehensive Cancer Network: JNCCN

journal
https://www.readbyqxmd.com/read/27799518/oncology-research-program
#1
(no author information available yet)
No abstract text is available yet for this article.
November 2016: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/27799517/correspondence
#2
LETTER
Arjun Gupta, Kah Poh Loh, Ankit Kansagra, Meng-Shiou Shieh, Penelope Pekow, Peter Lindenauer, Mihaela Stefan, Tara Lagu
No abstract text is available yet for this article.
November 2016: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/27799516/arguing-about-the-value-of-cancer-care
#3
Ivo Abraham, Ali McBride, Karen MacDonald
No abstract text is available yet for this article.
November 2016: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/27799515/use-of-nccn-guidelines-other-guidelines-and-biomarkers-for-colorectal-cancer-screening
#4
REVIEW
Christina D Williams, William M Grady, Leah L Zullig
Colorectal cancer (CRC) remains a common cancer and significant public health burden. CRC-related mortality is declining, partly due to the early detection of CRC through robust screening. NCCN has established the NCCN Guidelines for CRC Screening to help healthcare providers make appropriate screening recommendations according to the patient's risk of developing CRC. This review describes the evolution of CRC screening guidelines for average-risk individuals, discusses the role of NCCN Guidelines for CRC Screening in cancer prevention, and comments on the current and emerging use of biomarkers for CRC screening...
November 2016: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/27799514/tobacco-cessation-treatment-pathways-for-patients-with-cancer-10-years-in-the-making
#5
REVIEW
Maher Karam-Hage, Hanadi Ajam Oughli, Vance Rabius, Diane Beneventi, Rosario C Wippold, Janice A Blalock, Paul M Cinciripini
Tobacco use is the most common cause of preventable morbidity and mortality in the United States; it accounts for one-third of all cancer deaths and is thought to account for half of preventable cancer deaths. This article describes the Tobacco Treatment Program at a major academic cancer center. Patients and employees may access these services in a number of ways. All current smokers and recent quitters are proactively contacted and invited to participate. Services provided are tailored to the motivational level of individual patients and their immediate medical needs...
November 2016: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/27799513/smoking-cessation-version-1-2016-nccn-clinical-practice-guidelines-in-oncology
#6
Peter G Shields, Roy S Herbst, Douglas Arenberg, Neal L Benowitz, Laura Bierut, Julie Bylund Luckart, Paul Cinciripini, Bradley Collins, Sean David, James Davis, Brian Hitsman, Andrew Hyland, Margaret Lang, Scott Leischow, Elyse R Park, W Thomas Purcell, Jill Selzle, Andrea Silber, Sharon Spencer, Tawee Tanvetyanon, Brian Tiep, Hilary A Tindle, Reginald Tucker-Seeley, James Urbanic, Monica Webb Hooper, Benny Weksler, C Will Whitlock, Douglas E Wood, Jennifer Burns, Jillian Scavone
Cigarette smoking has been implicated in causing many cancers and cancer deaths. There is mounting evidence indicating that smoking negatively impacts cancer treatment efficacy and overall survival. The NCCN Guidelines for Smoking Cessation have been created to emphasize the importance of smoking cessation and establish an evidence-based standard of care in all patients with cancer. These guidelines provide recommendations to address smoking in patients and outlines behavioral and pharmacologic interventions for smoking cessation throughout the continuum of oncology care...
November 2016: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/27799512/psychotropic-and-opioid-medication-use-in-older-patients-with-breast-cancer-across-the-care-trajectory-a-population-based-cohort-study
#7
Ania Syrowatka, Sue-Ling Chang, Robyn Tamblyn, Nancy E Mayo, Ari N Meguerditchian
BACKGROUND: Older patients with breast cancer represent a vulnerable population at higher risk of experiencing distress and pain, as well as medication-related adverse events from pharmacological treatment of these symptoms. The purpose of this study is to estimate the prevalence of psychotropic (anxiolytic, antidepressant, and antipsychotic) and opioid medication use by older women diagnosed with breast cancer. METHODS: This population-based cohort study followed 19,353 women older than 65 years diagnosed with incident, nonmetastatic breast cancer in Quebec, Canada...
November 2016: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/27799511/high-risk-of-adverse-pathologic-features-in-patients-with-clinical-t1-high-grade-bladder-cancer-undergoing-radical-cystectomy
#8
Richard S Matulewicz, Brendan T Frainey, Daniel T Oberlin, Joshua J Meeks
BACKGROUND: Radical cystectomy (RC) is used to treat select patients with T1 high-grade (T1HG) bladder cancer. However, population-level utilization trends and outcomes for these patients are not well-known. We sought to evaluate treatment patterns and clinicopathologic outcomes of RC for T1HG bladder cancer. PATIENTS AND METHODS: Using the National Cancer Data Base (NCDB) for 1998-2012, we conducted a retrospective cohort study of patients with clinical T1HG bladder cancer...
November 2016: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/27799510/validation-of-the-kattan-nomogram-for-prostate-cancer-recurrence-after-radical-prostatectomy
#9
Rochelle Payne Ondracek, Michael W Kattan, Christine Murekeyisoni, Changhong Yu, Eric C Kauffman, James R Marshall, James L Mohler
BACKGROUND: The Kattan postoperative radical prostatectomy (RP) nomogram is used to predict biochemical recurrence-free progression (BCRFP) after RP. However, external validation among contemporary patients using modern outcome definitions is limited. METHODS: A total of 1,931 patients who underwent RP at Roswell Park Cancer Institute (RPCI) between 1993 and 2014 (median follow-up, 47 months; range, 0-244 months) were assessed for NCCN-defined biochemical failure (BF) and RPCI-defined treatment failure (TF)...
November 2016: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/27799509/on-the-effect-of-triplet-or-doublet-chemotherapy-in-advanced-gastric-cancer-results-from-a-national-cancer-registry
#10
Alberto Carmona-Bayonas, Paula Jiménez-Fonseca, Maria Luisa Sánchez Lorenzo, Avinash Ramchandani, Elena Asensio Martínez, Ana Custodio, Marcelo Garrido, Isabel Echavarría, Juana María Cano, Jose Enrique Lorenzo Barreto, Teresa García García, Felipe Álvarez Manceñido, Alejandra Lacalle, Marta Ferrer Cardona, Monserrat Mangas, Laura Visa, Elvira Buxó, Aitor Azkarate, Asunción Díaz-Serrano, Ana Fernández Montes, Fernando Rivera
BACKGROUND: There is currently no consensus regarding first-line chemotherapy for patients with advanced gastric cancer (AGC) who are ineligible to receive trastuzumab. The objective of this study was to evaluate the efficacy and tolerance of triplets versus doublets by analyzing a national gastric cancer registry. PATIENTS AND METHOD: Patients with AGC treated with polychemotherapy without associating trastuzumab were included from 2008 through 2016. The effect of triplets versus doublets was compared using 3 methods: Cox proportional hazards regression, propensity score matching (PSM), and coarsened exact matching (CEM)...
November 2016: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/27799508/refining-the-patient-navigation-role-in-a-colorectal-cancer-screening-program-results-from-an-intervention-study
#11
Elizabeth A Rohan, Beth Slotman, Amy DeGroff, Kerry Grace Morrissey, Jennifer Murillo, Paul Schroy
BACKGROUND: Oncology patient navigators help individuals overcome barriers to increase access to cancer screening, diagnosis, and timely treatment. This study, part of a randomized intervention trial investigating the efficacy of patient navigation in increasing colonoscopy completion, examined navigators' activities to ameliorate barriers to colonoscopy screening in a medically disadvantaged population. METHODS: This study was conducted from 2012 through 2014 at Boston Medical Center...
November 2016: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/27799507/nccn-guidelines-insights-older-adult-oncology-version-2-2016
#12
Noam VanderWalde, Reshma Jagsi, Efrat Dotan, Joel Baumgartner, Ilene S Browner, Peggy Burhenn, Harvey Jay Cohen, Barish H Edil, Beatrice Edwards, Martine Extermann, Apar Kishor P Ganti, Cary Gross, Joleen Hubbard, Nancy L Keating, Beatriz Korc-Grodzicki, June M McKoy, Bruno C Medeiros, Ewa Mrozek, Tracey O'Connor, Hope S Rugo, Randall W Rupper, Dale Shepard, Rebecca A Silliman, Derek L Stirewalt, William P Tew, Louise C Walter, Tanya Wildes, Mary Anne Bergman, Hema Sundar, Arti Hurria
Cancer is the leading cause of death in older adults aged 60 to 79 years. Older patients with good performance status are able to tolerate commonly used treatment modalities as well as younger patients, particularly when adequate supportive care is provided. For older patients who are able to tolerate curative treatment, options include surgery, radiation therapy (RT), chemotherapy, and targeted therapies. RT can be highly effective and well tolerated in carefully selected patients, and advanced age alone should not preclude the use of RT in older patients with cancer...
November 2016: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/27799506/personalized-treatment-for-a-patient-with-a-braf-v600e-mutation-using-dabrafenib-and-a-tumor-treatment-fields-device-in-a-high-grade-glioma-arising-from-ganglioglioma
#13
Silviya K Meletath, Dean Pavlick, Tim Brennan, Roy Hamilton, Juliann Chmielecki, Julia A Elvin, Norma Palma, Jeffrey S Ross, Vincent A Miller, Philip J Stephens, George Snipes, Veena Rajaram, Siraj M Ali, Isaac Melguizo-Gavilanes
BACKGROUND: Gangliogliomas are slow-growing, low-grade central nervous system tumors affecting children and young adults. However, some patients will experience tumor recurrence and/or malignant progression. This article reports on the clinical history, molecular findings, and treatment response in a patient with BRAF V600-mutated high-grade glioma arising from ganglioglioma. METHODS: Hematoxylin-eosin staining and comprehensive genomic profiling via Foundation One were performed on the tumor sample from a male patient undergoing treatment at the Department of Neuro-Oncology at Baylor University Medical Center...
November 2016: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/27799505/dissemination-and-implementation-of-guidelines-for-cancer-related-fatigue
#14
Ann M Berger, Kathi Mooney
No abstract text is available yet for this article.
November 2016: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/27799504/my-knee-hurts
#15
Margaret Tempero
No abstract text is available yet for this article.
November 2016: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/27697986/oncology-research-program
#16
(no author information available yet)
No abstract text is available yet for this article.
October 2016: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/27697985/ambulatory-oncology-operations-strategies-to-alleviate-complexity
#17
Chadi Nabhan, Sandeep Parsad
No abstract text is available yet for this article.
October 2016: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/27697984/multimodality-therapy-of-localized-gastric-adenocarcinoma
#18
Brian Badgwell
Surgical resection is the primary method of obtaining a potential cure for patients with gastric adenocarcinoma. However, chemotherapy or chemoradiotherapy offer significant improvement in survival over surgery alone. Much of the difficulty in deciding the optimal treatment strategy is choosing between perioperative chemotherapy or adjuvant chemoradiotherapy. Adding to the complexity is the potential for incorporating treatment strategies based on clinical trials performed in Asia. There is likely a difference in tumor biology between Eastern and Western patients with gastric adenocarcinoma, in addition to the clear differences in screening, pathologic assessment, and surgical technique...
October 2016: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/27697983/advances-in-systemic-therapy-for-metastatic-or-advanced-gastric-cancer
#19
Kohei Shitara, Atsushi Ohtsu
In recent years, various new agents have been investigated for the treatment of advanced gastric cancer (AGC). The anti-HER2 antibody trastuzumab has been shown to prolong the overall survival of patients with HER2-positive AGC and has become a standard treatment. However, lapatinib, or ado-trastuzumab emtansine (T-DM1), did not show survival benefit in AGC, although it has shown remarkable efficacy for HER2-positive breast cancer. The efficacy of the anti-vascular endothelial growth factor receptor monoclonal antibody ramucirumab for pretreated gastric cancer is a milestone for antiangiogenic therapy for AGC...
October 2016: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/27697982/gastric-cancer-version-3-2016-nccn-clinical-practice-guidelines-in-oncology
#20
Jaffer A Ajani, Thomas A D'Amico, Khaldoun Almhanna, David J Bentrem, Joseph Chao, Prajnan Das, Crystal S Denlinger, Paul Fanta, Farhood Farjah, Charles S Fuchs, Hans Gerdes, Michael Gibson, Robert E Glasgow, James A Hayman, Steven Hochwald, Wayne L Hofstetter, David H Ilson, Dawn Jaroszewski, Kimberly L Johung, Rajesh N Keswani, Lawrence R Kleinberg, W Michael Korn, Stephen Leong, Catherine Linn, A Craig Lockhart, Quan P Ly, Mary F Mulcahy, Mark B Orringer, Kyle A Perry, George A Poultsides, Walter J Scott, Vivian E Strong, Mary Kay Washington, Benny Weksler, Christopher G Willett, Cameron D Wright, Debra Zelman, Nicole McMillian, Hema Sundar
Gastric cancer is the fifth most frequently diagnosed cancer and the third leading cause of death from cancer in the world. Several advances have been made in the staging procedures, imaging techniques, and treatment approaches. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Gastric Cancer provide an evidence- and consensus-based treatment approach for the management of patients with gastric cancer. This manuscript discusses the recommendations outlined in the NCCN Guidelines for staging, assessment of HER2 overexpression, systemic therapy for locally advanced or metastatic disease, and best supportive care for the prevention and management of symptoms due to advanced disease...
October 2016: Journal of the National Comprehensive Cancer Network: JNCCN
journal
journal
40348
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"